



ASX Release
10th November 2025

Compumedics secures 5th and new \$4.9 million MEG sales order

Strong China demand fuels MEG growth, lifting total sales to \$25 million

Highlights

- New \$4.9 million MEG sales order from Beijing Normal University, China
- Total MEG orders now five, worth approximately \$25 million in contracted revenues
- Three systems to ship in FY26, with the newly secured system scheduled for FY27
- China expansion reinforces Compumedics' MEG leadership across Asia
- Continued progress toward North American market re-entry in 2026

Compumedics Limited (ASX: CMP) ("Compumedics" or "Company") is pleased to announce that, following the successful installation of its first Orion LifeSpan™ magnetoencephalography (MEG) system in China and with three more systems in production, the Company has secured a new \$4.9 million MEG order from the renowned Beijing Normal University. The sale is via Beijing Fistar, Compumedics' long-term Chinese distributor for the Company's brain research technology. This takes total MEG sales to five, representing about \$25 million in contracted revenues for Compumedics' growing neuro-imaging business.

The MEG system, along with a host of peripherals including simultaneous EEG, stimulators, computers, and CURRY neuroimaging software, will ship to Beijing Normal University in FY27, aligned with MEG production lead times. Compumedics expects to receive an initial deposit this month, with further milestone payments due on shipment and installation.

Beijing Normal University (BJNU) is one of China's top public universities, affiliated with the Ministry of Education and the Beijing Municipal Government. Recognised globally for excellence in education and research, BJNU ranks among the top 200 universities worldwide and 36th in the WURI Global Top Innovative Universities.

Expanding Leadership in Brain Imaging

This new contract strengthens Compumedics' position in China's rapidly expanding neuro-imaging and brain-research market. Beijing Normal University's selection followed a competitive technical review, reinforcing Compumedics' differentiation against global peers.

The Company continues to achieve milestones in advancing the Orion LifeSpan™ MEG, including high-quality dual-helmet recordings, hyperscanning from both MEG sensor arrays and powerful analysis capability via the newly released CURRY 9.

Investor Outlook

Compumedics' MEG business continues to scale, providing a clear pathway to sustainable revenue growth. The \$25 million MEG order book now underpins forward revenues through FY27, with additional opportunities being pursued across China, North America, and Europe.



Compumedics Global Neuro-Imaging Business Director, Gordon Haid said:

"We are once again pleased to announce a new sales order for an Orion LifeSpan™ MEG system from China following the successful installation and sales already achieved in the country. The unique features of the Orion LifeSpan, including dual measurement helmets, 100% helium recycling and CURRY software were once again significant factors in the selection of Compumedics as an MEG supplier."

Internationally renowned MEG/EEG expert Prof. Liu Yunzhe will serve as the chief expert of the BJNU MEG team. Prof. Liu has published numerous MEG-related research findings in top-tier journals such as Science, Cell and Nature Neuroscience. There is no doubt that this lays a solid foundation for Orion MEG's further expansion in the lucrative and expanding Chinese and international markets in the future."

Compumedics Executive Chairman, David Burton said:

"We are very proud to have received this latest and 5th MEG order from China, especially from such a prestigious university. The Chinese neurosciences market is proving to be an exciting and lucrative sector for the innovative MEG products being produced by the company. The BJNU order marks the most significant milestone yet in the Orion Lifespan's market penetration."

About Compumedics Neuroscan Orion LifeSpan™ MEG

MEG is a functional neuroimaging technique for mapping brain activity by recording magnetic fields produced by electrical currents occurring naturally in the brain using very sensitive detectors. Compumedics has revolutionised MEG with the Orion LifeSpan™'s increased precision coupled with fully integrated CURRY brain analysis software. Over a 30-year period Compumedics has established the gold standard in neurophysiological multi-modality (including MEG, EEG, MRI, CT, SPECT, PET) brain analysis software. In parallel, over a 30-year period our technology partner, the KRISS MEG team led by Dr. Yong-Ho Lee, have produced the most advanced MEG brain imaging scanner.

At the heart of the Orion LifeSpan™ are MEG sensors based on Double Relaxation Oscillation Superconducting Quantum Interference Devices (DROS SQUIDS), which are patented and exclusive. They are significantly more accurate than conventional MEG sensors.

Additionally, a unique dual-helmet dewar enables accurate measurements from adult and paediatric populations, along with hyperscanning. This includes a sensors-in-vacuum cooling system for more sensitive measurements. The dewar is coupled to a virtual 100% coolant recycling system with continuous operation. No refilling of helium is required and 24/7 operation is possible.

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a leading global medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the US, and DWL Elektronische GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia's Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.

For further information please contact:

Dr. David Burton
Executive Chairman, CEO
P: +61 3 8420 7300
F: +61 3 8420 7399

David Lawson
Director, CFO
P: + 61 3 8420 7300
F: +61 3 8420 7399

Authorised for lodgement by Compumedics Limited's Board of Directors